It seems that they saved data today, quite pointedly, for ASCO. The shorts selling their covers exacerbated the sector fall. Then, once retail realized today was a non-event, they dropped what the bots had picked up. MM's win again.
I was a fool. Bought at 3.55. I'll average down and buy the low big to establish a core position - long. I was really encouraged by what I heard today - unlike the science-challenged retail.
Call me crazy, sarcoma is awesome and all, but I like the low bar that Avastin sets for GBM. The uptake should be greater with Aldo., giving us a higher partial response rate and maybe A complete response. I believe Avastin was 48.9% partial, 0% complete. So yeah, like I said, low bar. (Side effects, even if proven to be better marginally, should still be better as Avastin is a horrible drug.)
I'm a little nervous about the plaintiff situation, but if all goes according to plan, the shorts covering on the 13th will make for an epic pre-ASCO rally. The suit is baseless anyway.
Can anyone confirm if the Bakers were at the Harvard Club today? TLR-tech. in dermatological proof-of-concept's seem to be their muse. I wouldn't be surprised if we see some SC-13's drop in our favor on the morning of the 14th - maybe even prior.
I'm done now. I'm excited.
It's a whole new bio market out there folks. Hit those lows and be careful about re-buying high. The game has changed to benefit the shorts and MM's. I know we'll likely see a 30% sell-off after the pop at ASCO - even if we are primed to replace Doxo. as SOC. Time is an enemy.
GL
AI
